Purificação e caracterização inicial de ativadores pró-coagulantes: ativadores de fator de II e/ou X do veneno da serpente Bothrops jararaca

Annually, about 40,000 persons are stricken by snake bite accidents in Brazil, being most of the cases are inflicted by Bothrops genus, whose venom can induce serious pathophysiological effects, mainly disorders in hemostasis. Bothrops jararaca venom is characterized by three main actions: proteolytic, coagulant and hemorrhagic. Some clotting factors can be activated by components present in the venom, classified as pro-coagulant activators, responsible for activating factor X or factor II of the coagulation cascade, generating thrombin. So far, only one procoagulant activator of Bothrops jararaca venom BjV has been characterized, bothrojaractivase, a 23 kDa PI-type metalloproteinase. In this work, we used chromatographic techniques to isolate other procoagulant components of BjV. Thus, by means of affinity chromatographies, BjV was purified on HisTrap and Blue Sepharose resins. Fractions capable of coagulating human fibrinogen and rabbit plasma were obtained, and this last substrate is only coagulated by pro-coagulant activators of BjV. Such fractions with high clotting activity were analyzed, concentrated and their activities on different substrates were differentiated by the use of specific inhibitors of metalloproteinases and serine proteinases. Studies are still being carried out to understand which coagulation factors are being activated by these fractions, by using chromogenic substrates, electrophoresis runs, and mass spectrometry.

Anualmente, cerca de 40.000 pessoas são acometidas por acidentes ofídicos no Brasil, sendo a maioria dos casos decorrentes de serpentes do gênero Bothrops, cujo veneno pode induzir graves efeitos fisiopatológicos, principalmente distúrbios na hemostasia. O veneno da espécie Bothrops jararaca é caracterizado por três ações principais: proteolítica, coagulante e hemorrágica. Relacionado à atividade coagulante, alguns fatores da cascata de coagulação podem ser ativados por componentes presentes no veneno, classificados como ativadores do tipo pró-coagulantes, responsáveis por ativar o fator X ou o fator II da cascata, gerando trombina. Até o momento, apenas um ativador pró-coagulante do veneno de Bothrops jararaca BjV foi caracterizado, a bothrojaractivase, uma metaloproteinase do tipo PI, de 23 kDa. Neste trabalho, utilizamos técnicas cromatográficas para isolar outros componentes pró-coagulantes do BjV. Deste modo, por meio de cromatografias de afinidade, o BjV foi purificado em resinas de HisTrap e Blue Sepharose. Foram obtidas frações capazes de coagular o fibrinogênio humano e plasma de coelho, um substrato que somente é coagulado por enzimas pró-coagulantes do BjV. Tais frações com altas atividades coagulantes foram analisadas, concentradas e suas atividades sobre diferentes substratos foram diferenciadas pelo uso de inibidores específicos de metaloproteinases e serinaproteinases. Obtivemos duas frações parcialmente purificadas, com alta atividade específica, e que são inibidas por quelante de metais divalentes o-fenantrolina. Essas frações são capazes de coagular o plasma de coelho, sem coagular o fibrinogênio humano. Estudos ainda estão sendo realizados para entender quais fatores da cascata de coagulação estas frações ativam, pela utilização de substratos cromogênicos específicos, análises eletroforéticas e espectrometria de massa.

Anti-inflammatory effect of Bougainvillea × buttiana (Var. Orange) extract in experimental Bothrops jararaca envenomation

Background: Bougainvillea x buttiana is a plant used in folk Mexican medicine to treat different inflammatory diseases. Objective: In this study, the anti-inflammatory effect of B. x buttiana orange extract (BxbO) was evaluated on edema formation, cytokine production, and lethality in mice in response to venom of Bothrops jararaca (VBj) snake. Materials and Methods: The BxbO extract was tested in vitro to determine its effect on phospholipase A2(PLA2) and in vivo for the formation of edema, the paw edema model was used, as well as the toxicity of the extract and the production of cytokines. Lethality induced by VBj, the survival percentage, was calculated. Results: BxbO extract significantly inhibited in vitro PLA2and in vivo, blocked the edema formation and cytokine production, and prevented lethality induced by VBj. The constituents of BxbO may bind to components of VBj, such as PLA2, thereby blocking the proteolytic action of the venom. In animals treated with BxbO extract injected 1 h after the venom injection, no difference was observed in the cytokine secretion. In contrast, for all mice treated with BxbO extract for 1 h before VBj administration or together with VBj, the pro-inflammatory cytokine secretion in the serum was attenuated and an exacerbated production anti-inflammatory cytokine. In the presence of the BxbO extract injected 1 h before the VBj injection or together with the VBj injection, mortality was significantly lower. Conclusion: Altogether, our results show that BxbO extract can inhibit the local and systemic activities of VBj. However, new studies are still required to identify the interaction mechanisms between bioactive compounds and cellular components.

LTB4 and PGE2 modulate the release of MIP-1α and IL-1ß by cells stimulated with Bothrops snake venoms.

Envenomation by Bothrops snakes promotes the release of inflammatory mediators, whose effects during this context are not well understood. These mediators include chemokines, cytokines and eicosanoids. Indeed, Bothrops snake envenomation results in local and systemic perturbations, including leukocyte recruitment, edema, pain and extensive tissue damage. Recently, our group demonstrated that leukotriene B4 (LTB4) and prostaglandin E2 (PGE2) regulate macrophage production of interleukin-1ß (IL-1ß) induced by scorpion venom. Whether these molecular mechanisms also affect host cell responses to snake venoms, such as those from B. jararaca or B. jararacussu, is unknown. In this study, we demonstrate that B. jararaca or B. jararacussu venoms induce macrophage inflammatory protein 1-alpha (MIP-1α) and IL-1ß production by THP-1 (cell line of human peripheral blood monocytes) and AMJ2-C11 (cell line of mouse alveolar macrophage). We also show that venoms from both Bothrops species induce NF-κB activation in THP-1 cells. Furthermore, we observed that treatment of THP-1 and AMJ2-C11 cell lines with exogenous PGE2 reduces MIP-1α production, while increasing IL-1ß production in cells stimulated by B. jararaca or B. jararacussu venoms. Interestingly, exogenous LTB4 had the opposite effect by reducing IL-1ß and increasing MIP-1α release. Our results suggest that, differential eicosanoid metabolism in myeloid cells is tightly associated with the production of cytokines and chemokines after stimulation with B. jararaca or B. jararacussu venoms.

In vitro cleavage of bioactive peptides by peptidases from Bothrops jararaca venom and its neutralization by bothropic antivenom produced by Butantan Institute: Major contribution of serine peptidases.

In Brazil, envenomation by Bothrops pitvipers is responsible for over 73% of snakebites, and their venom is a rich source of proteolytic enzymes. Most studies have demonstrated that Bothrops jararaca venom acts on macromolecular substrates, causing an imbalance in the victim's hemostatic system. In contrast, fewer studies have examined the proteolytic activity on small molecules such as peptides. In this study, we used a set of bioactive peptides (insulin B chain, Met-enkephalin, Leu-enkephalin, neuropeptide Y, peptide YY, pancreatic polypeptide, substance P and somatostatin) to identify new peptide substrates for the metallopeptidases and serine peptidases from the B. jararaca venom. The majority of these peptides were substrates for the venom, but neuropeptide Y and pancreatic polypeptide presented higher hydrolyses rates. Although most of the peptides were simultaneously substrates for both classes of proteases, serine peptidases were the most active. Substance P was an exclusive substrate for metallopeptidases, while somatostatin was a selective substrate for serine peptidases. The neutralizing efficacy of the bothropic antivenom produced by the Butantan Institute was also assessed and found to totally prevent substance P hydrolysis, whereas somatostatin cleavage was not inhibited. Thus, the antivenom effectively inhibited metallopeptidase activity, but did not neutralize some of the serine peptidases. These results indicate that, in addition to cleaving proteins, the proteolytic enzymes from this venom also hydrolyze bioactive peptides, and this peptidase activity could effectively contribute to some of the many dire manifestations of envenomation.

Peptides derived from plasma proteins released by bothropasin, a metalloprotease present in the Bothrops jararaca venom.

Viperid snake venoms contain proteases that affect hemostasis by degrading important proteins such as those that participate in the coagulation cascade. The Bothrops jararaca venom presents as its main components metallo and serine proteases, which comprise around 65% of the venom composition. Bothropasin is a hemorrhagic metalloprotease from the B. jararaca venom which causes disruption of the basement membrane of the vascular endothelium, resulting in bleeding. Although the bothropasin ability to degrade plasmatic and extracellular matrix proteins in vitro has been described, the primary sequence of the released peptides is unknown. This research study presents the peptide identification from both fibrinogen and fibronectin, generated by bothropasin proteolytic activity. Among the fibrinogen derived peptides identified by mass spectrometry, analogous of endogenous products like the fibrinopeptides A and B were found, as well as other sequences described in the literature with vasoactive or antiangiogenic properties. A series of peptides derived from fibronectin by the action of bothropasin were described, and for most of them no biological activity has been described. However, exceptionally a peptide that is known as a bond site for B cells was found. This study indicates that, beyond to the degradation of human proteins, bothropasin can generate bioactive peptides, which may participate in the envenoming process by Bothrops snakes. Also important, the knowledge of the formed peptides, based on the cleavage sites of the hydrolyzed proteins, provided the opportunity to study the primary specificity of bothropasin.

Differences between renal effects of venom from two Bothrops jararaca populations from southeastern and southern Brazil.

Components from animal venoms may vary according to the snake's age, gender and region of origin. Recently, we performed a proteomic analysis of Bothrops jararaca venom from southern (BjSv) and southeastern (BjSEv) Brazil, showing differences in the venom composition, as well as its biological activity. To continue the study, we report in this short communication the different effects induced by the BjSEv and BjSv on isolated kidney and MDCK renal cells. BjSEv decreased perfusion pressure (PP) and renal vascular resistance (RVR) and increased urinary flow (UF) and glomerular filtration rate (GFR), while BjSv did not alter PP and RVR and reduced UF and GFR. Both types of venom, more expressively BjSEv, reduced %TNa+, %TK+ and %Cl-. In MDCK cells, the two types of venom showed cytotoxicity with IC50 of 1.22 µg/mL for BjSv and 1.18 µg/mL for BjSEv and caused different profiles of cell death, with BjSv being more necrotic. In conclusion, we suggest that BjSv is more nephrotoxic than BjSEv.

Exploiting the antithrombotic effect of the (pro)thrombin inhibitor bothrojaracin.

Bothrojaracin is a 27 kDa C-type lectin-like protein from Bothrops jararaca snake venom. It behaves as a potent thrombin inhibitor upon high-affinity binding to thrombin exosites. Bothrojaracin also forms a stable complex with prothrombin that can be detected in human plasma. Formation of the zymogen-inhibitor complex severely decreases prothrombin activation and contributes to the anticoagulant activity of bothrojaracin. In the present study, we employed two rodent models to evaluate the antithrombotic effect of bothrojaracin in vivo: stasis-induced thrombosis and thrombin-induced pulmonary thromboembolism. It was observed that bothrojaracin interacts with rat prothrombin in plasma. Ex-vivo assays showed stable complex formation even after 24 h of a single bothrojaracin dose. As a result, bothrojaracin showed significant antithrombotic activity in a rat venous thrombosis model elicited by thromboplastin combined with stasis. The antithrombotic activity of bothrojaracin (1 mg/kg) persisted for up to 24 h and it was associated with moderate bleeding as assessed by a tail transection method. Formation of bothrojaracin-prothrombin complex has been also observed following intravenous administration of the inhibitor into mice. As a result, bothrojaracin effectively protected mice from thrombin-induced fatal thromboembolism. We conclude that bothrojaracin is a potent antithrombotic agent in vivo and may serve as a prototype for the development of new zymogen-directed drugs that could result in prolonged half-life and possible decreased hemorrhagic risk.

Proteomic identification of gender molecular markers in Bothrops jararaca venom.

Variation in the snake venom proteome is a well-documented phenomenon; however, sex-based variation in the venom proteome/peptidome is poorly understood. Bothrops jararaca shows significant sexual size dimorphism and here we report a comparative proteomic/peptidomic analysis of venoms from male and female specimens and correlate it with the evaluation of important venom features. We demonstrate that adult male and female venoms have distinct profiles of proteolytic activity upon fibrinogen and gelatin. These differences were clearly reflected in their different profiles of SDS-PAGE, two-dimensional electrophoresis and glycosylated proteins. Identification of differential protein bands and spots between male or female venoms revealed gender-specific molecular markers. However, the proteome comparison by in-solution trypsin digestion and label-free quantification analysis showed that the overall profiles of male and female venoms are similar at the polypeptide chain level but show striking variation regarding their attached carbohydrate moieties. The analysis of the peptidomes of male and female venoms revealed different contents of peptides, while the bradykinin potentiating peptides (BPPs) showed rather similar profiles. Furthermore we confirmed the ubiquitous presence of four BPPs that lack the C-terminal Q-I-P-P sequence only in the female venom as gender molecular markers. As a result of these studies we demonstrate that the sexual size dimorphism is associated with differences in the venom proteome/peptidome in B. jararaca species. Moreover, gender-based variations contributed by different glycosylation levels in toxins impact venom complexity. BIOLOGICAL SIGNIFICANCE: Bothrops jararaca is primarily a nocturnal and generalist snake species, however, it exhibits a notable ontogenetic shift in diet and in venom proteome upon neonate to adult transition. As is common in the Bothrops genus, B. jararaca shows significant sexual dimorphism in snout-vent length and weight, with females being larger than males. This sexual size dimorphism suggests the tendency for female specimens to feed on larger prey, and for male specimens to go on a diet similar to that of juveniles. Variation in the snake venom proteome is a ubiquitous phenomenon occurring at all taxonomic levels. At the intraspecific variation level, the individual contribution to the venom proteome is important but effects contributed by age and feeding habits may also affect the proteome phenotype. Whether sex-based factors play a role in venom variation of a species that shows sexual size dimorphism is poorly known. The use of proteomic strategies supported by transcriptomic data allows a more comprehensive assessment of venom proteomes uncovering components that are gender-specific.

The Anti-Inflammatory Effects of the Methanolic Extract and Fractions from Davilla elliptica St. Hil. (Dilleniaceae) on Bothrops jararaca Envenomation.

Inflammation and haemorrhage are the main characteristics of tissue injury in botropic envenomation. Although some studies have shown that anti-venom prevents systemic reactions, it is not efficient in preventing tissue injury at the site of the bite. Therefore, this work was undertaken to investigate the anti-inflammatory effects of the methanolic extract and fractions from D. elliptica and to evaluate the role of matrix metalloproteinases (MMPs) in this process. Effects of the extract and fractions from D. elliptica were evaluated using a carrageenan-induced paw oedema model in rats, and leukocyte rolling was visualized by intravital. The quantification of MMPs activities (MMP-2 and MMP-9) extracted from the dermis of mice treated with extract and fractions alone or incubated with venom was determined by zymographic analyses. Our results show that intraperitoneal (i.p.) injection of fractions significantly reduced paw oedema after the carrageenan challenge. Treatment with the tannins fraction also resulted in considerable inhibition of the rolling of leukocytes and this fraction was able to decrease the activation of MMP-9. These results confirmed the anti-inflammatory activity of the methanolic extract and tannins fraction of D. elliptica and showed that the dermonecrosis properties of B. jararaca venom might be mediated through the inhibition of MMP-9 activity.

An alternative micromethod to access the procoagulant activity of Bothrops jararaca venom and the efficacy of antivenom.

The assessment of the capacity of antivenoms to neutralize the lethal activity of snake venoms still relies largely on traditional rodent lethality assay (LD50). However, adequately validated in vitro tests should be introduced for assessing antivenom neutralizing capacity in plasma of immunized horses as well as for in-process quality control. The dynamic of fibrin formation in recalcified avian plasma samples is extremely slow, when compared to that presented by mammalian plasmas. In this study, we present one new coagulant assay, by performing dose-response curve after plotting the clotting time (CT) parameter of the ROTEM profile of recalcified chicken plasma samples (target) against semi-logarithmic doses of Bothrops jararaca venom (agonist), either in absence or in presence of the semi-logarithmic doses of anti-bothropic serum (ABS) (antagonist). The mean coagulant dose 50% (CD50) was defined as the quantity of venom (in µg) which reduces CT to 900 s, between minimum and maximum responses. The CT induced by 5CD50 of the venom was used as the control for calculating the effective dose (ED) of each batch of ABS. ED was defined as the ABS dose (nanoliters, nL) at which CT induced by one amount of venom corresponding to 5CD50 is displaced to the maximum threshold (1800 s). Five batches of the ABS, previously assayed for their lethality neutralizing activity (ED50) were assayed. The correlation coefficient (r) between both in vitro (ED) and in vivo (ED50) values was 0.87 (p value < 0.05). We propose this micro method as highly sensitive for characterization and quantification of possible procoagulant activity of small doses of snake venoms (nanograms) and for detecting small doses (nanoliters) of specific antibodies against this effect in little volume samples of biological fluids.